Experimental Hematology & Oncology publishes preclinical, basic, patient-oriented and translational research in all areas of hematology and oncology. The journal acts as an international platform for sharing laboratory findings and makes a deliberate effort to publish clinical trials with 'negative' results, as well as basic science studies with provocative findings. This peer-reviewed, open access journal offers impressive turnaround times with a time to first decision of less than 30 days.
Experimental Hematology & Oncology
Description
Identifiers
e-ISSN | 2162-3619 |
Publisher
BioMed Central
Additional information
Data set: Springer
Articles
Experimental Hematology & Oncology > 2019 > 8 > 1 > 1-8
Background Second allogeneic hematopoietic stem cell transplant (HCT) remains as an option for disease relapse after initial HCT. Methods We analyzed retrospectively the outcomes of 65 consecutive patients who underwent a second HCT for disease relapse at the University of Chicago. Univariate and multivariate analysis were conducted, and a scoring system was generated to select the patients who...
Experimental Hematology & Oncology > 2019 > 8 > 1 > 1-7
Background Hepatoblastoma is the most common hepatic malignancy in children, accounting for approximately 80% of all childhood liver tumors. KRAS and NRAS, members of the RAS gene family, are closely linked to tumorigenesis, and are frequently mutated in a variety of malignancies. They may thus play critical roles in tumorigenesis. However, there are few studies on the association between the RAS...
Experimental Hematology & Oncology > 2019 > 8 > 1 > 1-8
Background Many cases of acute lymphoblastic leukemia (ALL) carry visible acquired chromosomal changes of pathogenetic, diagnostic, and prognostic importance. Nevertheless, from one-fourth to half of newly diagnosed ALL patients have no visible chromosomal changes detectable by G-banding analysis at diagnosis. The introduction of powerful molecular methodologies has shown that many karyotypically...